報價延遲最少15分鐘:2026/03/21 10:09 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
20.74 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
2.30/0.86
|
|
企業價值
3.55B
|
| 資產負債 |
|
每股賬面淨值
7.20
|
| 現金流量 |
|
現金流量率
0.03
|
| 損益表 |
|
收益
1.07B
|
|
每股收益
3.73
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs. |
